Viewing Study NCT00516945



Ignite Creation Date: 2024-05-05 @ 6:36 PM
Last Modification Date: 2024-10-26 @ 9:35 AM
Study NCT ID: NCT00516945
Status: COMPLETED
Last Update Posted: 2013-09-05
First Post: 2007-08-15

Brief Title: A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers
Sponsor: Hospital Authority Hong Kong
Organization: Hospital Authority Hong Kong

Study Overview

Official Title: A Randomized Controlled Study Comparing the Impact of Prophylactic Versus Deferred Lamivudine on the Delivery of Cytotoxic Chemotherapy in Hepatitis B Surface-antigen Positive Patients With Malignant Solid Tumor
Status: COMPLETED
Status Verified Date: 2013-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Patients with non-lymphoma and non-leukaemia cancer who are also hepatitis B carriers will have a risk of hepatitis B reactivation during chemotherapy Lamivudine can be used effectively to control hepatitis upon reactivation during chemotherapy and the chemotherapy may not need to be interrupted The study aims to investigate whether adding the anti-viral drug Lamivudine at the start of chemotherapy for all patients rather than at the time of hepatitis reactivation for those with reactivation will help to improve the delivery of chemotherapy in these patients
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
HARECCTR0500016 None None None